Home › Research › Treatments
Cost-Effectiveness of Donanemab for Early Alzheimer Disease in Australia
Lan Gao, R Watson, Nawaf Yassi. Deakin Research Online (Deakin University), 2026-04-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Donanemab increased total healthcare costs ($300,689 vs. $178,121) and societal costs ($389,113 vs. $283,618) compared with standard care per capita, while improving health outcomes (4.38 vs. 4.01 QALYs) per capita. The ICER was $342,424 per QALY from the healthcare perspective and $294,701 per QALY from the societal perspective, exceeding frequently cited Australian willingness-to-pay thresholds. Sensitivity analyses identified drug cost and efficacy as key drivers of uncertainty. Distributional analysis suggested inequitable health gains by remoteness because of differences in diagnostic and treatment infrastructure. Donanemab provides clinical benefits but is unlikely to be cost-effective under current Australian thresholds. Policymakers should balance economic evidence with unmet need, equity considerations and healthcare sustainability when making reimbursement decisions. Further research using real-world evidence and disaggregated analyses by geography and socioeconomic status is warranted.
What this study adds
Evidence grade: Moderate
Donanemab improved health outcomes compared with standard care but raised healthcare and societal costs, with cost-effectiveness ratios exceeding frequently cited Australian willingness-to-pay thresholds. It is unlikely to be cost-effective under current Australian thresholds, and health gains appeared inequitable by remoteness.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Gao, L., Watson, R., & Yassi, N. (2026). Cost-Effectiveness of Donanemab for Early Alzheimer Disease in Australia. Deakin Research Online (Deakin University). https://doi.org/10.26187/deakin.32142121
Vancouver
Gao L, Watson R, Yassi N. Cost-Effectiveness of Donanemab for Early Alzheimer Disease in Australia. Deakin Research Online (Deakin University). 2026. doi:10.26187/deakin.32142121.
BibTeX
@article{gao2026-91bcd677,
author = {Gao, Lan and Watson, R and Yassi, Nawaf},
title = {{Cost-Effectiveness of Donanemab for Early Alzheimer Disease in Australia}},
journal = {Deakin Research Online (Deakin University)},
year = {2026},
doi = {10.26187/deakin.32142121},
url = {https://doi.org/10.26187/deakin.32142121}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Donanemab increased total healthcare costs ($300,689 vs. $178,121) and societal costs ($389,113 vs. $283,618) compared with standard care per capita, while improving health outcomes (4.38 vs. 4.01 QALYs) per capita.
- The ICER was $342,424 per QALY from the healthcare perspective and $294,701 per QALY from the societal perspective, exceeding frequently cited Australian willingness-to-pay thresholds.
- Sensitivity analyses identified drug cost and efficacy as key drivers of uncertainty.
- Distributional analysis suggested inequitable health gains by remoteness because of differences in diagnostic and treatment infrastructure.
- Donanemab provides clinical benefits but is unlikely to be cost-effective under current Australian thresholds.
Why it matters
Donanemab improved health outcomes compared with standard care but raised healthcare and societal costs, with cost-effectiveness ratios exceeding frequently cited Australian willingness-to-pay thresholds. It is unlikely to be cost-effective under current Australian thresholds, and health gains appeared inequitable by remoteness.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthModerate
How this study scored 32/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record and institution's track record, so those were left out: it earned 30 of the 93 points we could judge it on, which is 32 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Deakin Research Online (Deakin University)) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Nawaf Yassi: h-index 43 (OpenAlex, whole career) |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Points | 30 / 93 | Scored on 18 of 20 parts. We have no data for the rest, so they are left out: 30 of the 93 points we could judge it on is 32 out of 100. |
| Total | 32 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.26187/deakin.32142121
- Original source →
- Free full text: Deakin Research Online (Deakin University) →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.